Drug Insight: Vascular disrupting agents and angiogenesis - Novel approaches for drug delivery

Nature Clinical Practice Oncology

Volumn 3, Issue 12, 2006, Pages 682-692

  Cooney, Matthew M ^a   van Heeckeren, Willem ^a   Bhakta, Shyam ^a   Ortiz, Jose ^a   Remick, Scot C ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; AURISTATIN PE; BEVACIZUMAB; CARBOPLATIN; COLCHICINE; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; EXHERIN; LENALIDOMIDE; MITOFLAXONE; MN 029; N ACETYLCOLCHINOL PHOSPHATE; PAZOPANIB; PODOPHYLLOTOXIN; SEMAXANIB; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SORAFENIB; SUNITINIB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR TARGETING AGENT; VINBLASTINE; VINCRISTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ALOPECIA; ANGIOGENESIS; ANXIETY DISORDER; AREA UNDER THE CURVE; ATAXIA; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PAIN; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CELL SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFUSION; DIARRHEA; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DYSGEUSIA; DYSPNEA; ELECTROCARDIOGRAPHY; ENDOTHELIUM CELL; FATIGUE; FLUSHING; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE CONDUCTION; HOT FLUSH; HUMAN; HYPOTENSION; HYPOXIA; KIDNEY CARCINOMA; LIPOSARCOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THYROID CANCER; TREMOR; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VASCULAR ENDOTHELIUM; VISUAL IMPAIRMENT; VOMITING;

ANGIOGENESIS INHIBITORS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33751583518     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0663     Document Type: Review

References (73)

1. Okamura J et al. (1982) An appraisal of transcatheter arterial embolization combined with transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies. World J Surg 6: 352-357
2. Patt YZ et al. (1983) Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. Cancer 51: 1359-1363
3. Soulen MC (1994) Chemoembolization of hepatic malignancies. Oncology 8: 77-84
4. Denekamp J et al. (1991) Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 20 (Suppl): 103-112
5. Arap W et al. (1999) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380
6. Schnitzer JE (1998) Vascular targeting as a strategy for cancer therapy. N Engl J Med 339: 472-474
7. Griggs J et al. (2001) Targeting tumour vasculature: The development of combretastatin A4. Lancet Oncol 2: 82-87
8. Pluda JM (1997) Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24: 203-218
9. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685-693
10. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62
11. Neri D et al. (2005) Tumor vascular targeting. Nat Rev Cancer 5: 436-446
12. Matsumura Y et al. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanisms of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 6: 6387-6392
13. Benjamin LE et al. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165
14. Darland DC et al. (1999) Blood vessel maturation: Vascular development comes of age. J Clin Invest 103: 157-158
15. Chaplin DJ et al. (1996) Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer 74: S86-S88
16. Hill SA et al. (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 199-223
17. Kerr DJ et al. (1989) Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol 25: 1271-1272
18. Chabot GG et al. (1993) Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse. Eur J Cancer 29: 729-733
19. Hill SA et al. (1989) Vascular collapse after flavone acetic acid: A possible mechanism of its antitumour action. Eur J Cancer 25: 1419-1424
20. Baguley BC et al. (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicines: Evidence for a vascular mechanism. Eur J Cancer 27: 482-487
21. Hill SA et al. (1993) Vinca alkaloids: Anti-vascular effects in a murine tumour. Eur J Cancer 29: 1320-1324
22. Bibby MC et al. (1989) Reduction of tumor blood flow by flavone acetic acid: A possible component to therapy. J Natl Cancer Inst 81: 216-220
23. Kallinowski F et al. (1989) In vivo targets of recombinant human tumour necrosis factor-alpha blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer 60: 555-560
24. Zwi LJ et al. (1989) Blood flow failure as a major determinant in the anti-tumor action of flavone acetic acid. J Natl Cancer Inst 81: 1005-1013
25. Ludford RJ (1985) Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst 6: 89-101
26. Dark GG et al. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834
27. Cooney MM et al. (2004) Cardiovascular safety profile of combretastatin A4 phosphate (CA4P) in a single-dose phase I pharmacokinetic study in patients with advanced cancer. Clin Cancer Res 10: 96-100
28. c interval data in a phase I study in patients with advanced cancer. Clin Cancer Res 10: 5967-5969
29. Cooney MM et al. (2004) Invited Letter to the Editor in response to Varterasian M et al. letter/commentary on the cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I trial in patients with advanced cancer. Clin Cancer Res 10: 5967-5969
30. van Heeckeren WJ et al. (2006) The promise of new vascular disrupting agents balanced with cardiac toxicity: Is it time that oncologists get to know their cardiologists? J Clin Oncol 24: 1485-1488
31. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186
32. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6
33. Kerbel RS (2000) Tumor angiogenesis: Past, present, and near future. Carcinogenesis 21: 505-515
34. Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
35. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
36. Kerbel RS et al. (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 6: 423-436
37. Teicher BA (1999) Combination of antiangiogenic agents with standard cytotoxic therapies in therapeutic regimens. Clin Cancer Res 5: 3878s-3879s.
38. Teicher BA et al. (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704
39. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434
40. Sandler AB et al (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599 [abstract]. Proc Am Soc Clin Oncol 23 (Suppl): 2S
41. Willett CG et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147
42. Siemann DW and Shi W (2003) Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13: 53-61
43. Ellis LM et al. (2001) Overview of angiogenesis: Biological implications for antiangiogenic therapy. Semin Oncol 28: 94-104
44. Siemann DW and Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in the treatment of solid tumors. Int J Radiat Oncol Biol Phys 60: 1233-1240
45. 3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site. Biochem Mol Biol Int 35: 1153-1159
46. Woods JA et al. (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-04. Br J Cancer 71: 705-711.
47. Comment in: Hemel E et al. (1983) Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Pharmacology 32: 3863-3867
48. Dark GG et al. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834
49. Vincent L et al. (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115: 2992-3006
50. Dowlati A et al. (2002) Phase I pharmacokinetic and translational study of the novel vascular targeting agent Combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416
51. Anderson HL et al. (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A-4 phosphate. J Clin Oncol 21: 2823-2830
52. Rustin GJS et al. (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 21: 2815-2822
53. Stevenson JP et al. (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21: 4428-4438
54. Bilenker JH et al. (2005) Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 11: 1527-1533
55. Ng QS et al. (2005) Phase Ib trial of combretastatin A4 phosphate in combination with radiotherapy (RT): Initial clinical results [abstract # 3117]. Proc Am Soc Clin Oncol 23 (Suppl): 221S
56. Zhou S et al. (2002) 5,6-dimethylxanthenone-4-acetic acid (DMXAA): A new biological response modifier for cancer therapy. Invest New Drugs 20: 281-295
57. Kelland LR et al. (2005) Plasma levels of 5-hydroxyindole acetic acid (5-HIAA) as a pharmacodynamic marker of blood flow changes induced by the vascular targeting agent (VTA) 5,6-dimethylxanthenone-4-acetic acid, DMXAA [abstract # 3123]. Proc Am Soc Clin Oncol 23 (Suppl): 222S
58. Galbraith SM et al. (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20: 3826-3840
59. Jameson MB et al. (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88:1844-1850
60. McKeage M et al. (2005) DART - a phase I safety and dose-finding study of the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in the treatment of refractory tumors [abstract # 3081]. Proc Am Soc Clin Oncol 23 (Suppl): 212S
61. Otani M et al. (2000) TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91: 837-844
62. Schoffski P et al. (2004) Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 15: 671-679
63. de Jonge MJA et al. (2005) Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11: 3806-3813
64. Blagen S et al. (2005) Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on day 1 (T and C) and day 8 (C) every three weeks in patients (pts) with advanced solid tumors [abstract # 3141]. Proc Am Soc Clin Oncol 23 (Suppl): 226S
65. Blakey DC et al. (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974-1983
66. Davis PD et al. (2002) A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253
67. Scurr M et al. (2004) Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumors [abstract # 3083]. Proc Am Soc Clin Oncol 22 (Suppl): 215S
68. DelProposto Z et al. (2002) MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature [abstract # 440]. Proc Am Soc Clin Oncol 20 (Suppl): 111S
69. Jonker DJ et al. (2005) A phase I study of the novel molecularly targeted vascular targeting agent, Exherin™ (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression [abstract # 3038]. Proc Am Soc Clin Oncol 23: 201S
70. Lejune P et al. (2002) In vivo antitumor activity and tumor necrosis induced by AVE8062, a tumor vasculature targeting agent [abstract #781]. AACR Proceedings 43 (Suppl): 156S
71. Gadgeel SM et al. (2002) A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [abstract # 438]. Proc Am Soc Clin Oncol 20: 110S
72. Klement G et al. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24
73. Browder T et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886